Sarepta Therapeutics
SRPT
$16.21
-3.68%
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on discovering and developing RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly Duchenne muscular dystrophy (DMD). The company is a leader in DMD treatments with approved therapies including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, positioning it as a dominant player in the neuromuscular rare disease space. The current investor narrative centers on the company's ability to sustain revenue growth from its DMD franchise while managing high R&D costs and achieving profitability, as recent quarterly results have shown significant volatility in earnings and cash flow. Key debates include the trajectory of ELEVIDYS adoption, pipeline progress in gene therapies, and the path to consistent positive net income.…
SRPT
Sarepta Therapeutics
$16.21
SRPT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Sarepta Therapeutics's 12-month outlook, with a consensus price target around $22.17 and implied upside of +36.8% versus the current price.
Average Target
$22.17
0 analysts
Implied Upside
+36.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$5 - $38
Analyst target range
Sarepta is covered by 24 analysts, with a consensus recommendation of 'Hold' (mean rating 2.75 on a 1-5 scale, where 1 is Strong Buy and 5 is Sell). The average target price is $22.08, implying approximately 28% upside from the current price of $17.22. The distribution shows a mix of bullish and bearish views: the high target of $38.00 suggests potential for significant upside if pipeline catalysts or revenue acceleration materialize, while the low target of $5.00 reflects downside risk from competitive pressures or regulatory setbacks. Recent institutional ratings include a mix of Outperform (Oppenheimer, Mizuho, Wedbush) and Sell/Underperform (Needham, Citigroup, HC Wainwright), indicating deep disagreement among analysts. The wide spread between high and low targets ($5 to $38) signals high uncertainty about the company's future performance. The consensus 'Hold' rating suggests analysts are waiting for clearer signs of sustainable profitability or pipeline progress before becoming more bullish.
Bulls vs Bears: SRPT Investment Factors
Sarepta presents a high-risk, high-reward opportunity. The bull case rests on a deeply discounted forward P/S ratio of 1.03x, a strong cash position, and potential for a short squeeze, while the bear case is driven by a 32.7% revenue decline, gross margin collapse to 9.98%, and negative free cash flow. The single most important tension is whether the Q4 2025 revenue and margin deterioration is a temporary setback or the start of a structural decline in the DMD franchise. Currently, the bearish evidence is stronger due to the severity of the Q4 miss, but the low valuation provides a margin of safety that could reward patient investors if the company stabilizes.
Bullish
- Forward P/S near 1x implies deep value: The forward price-to-sales ratio of 1.03x is extremely low compared to the biotech industry average of ~6.5x, suggesting the market is pricing in significant revenue growth or margin improvement. If Sarepta meets its estimated revenue of $1.28 billion, the current valuation offers a substantial margin of safety.
- Analyst average target implies 28% upside: The consensus analyst target price of $22.08 represents 28% upside from the current price of $17.22. Even the high target of $38.00 suggests potential for more than 120% gain if pipeline catalysts or revenue acceleration materialize.
- Strong cash position and manageable debt: Sarepta holds $814.4 million in cash with a current ratio of 2.32 and debt-to-equity of 0.91, indicating a solid liquidity position. This provides a buffer to fund operations and R&D without immediate financing risk.
- Elevated short interest could fuel a squeeze: The short ratio of 7.43 days indicates high short interest, which could lead to a short squeeze if positive catalysts emerge, such as better-than-expected earnings or pipeline progress. This could drive rapid price appreciation.
Bearish
- Q4 2025 revenue collapsed 32.7% YoY: Revenue fell from $658.4 million in Q4 2024 to $442.9 million in Q4 2025, a decline of 32.7%. This sharp deceleration raises concerns about the sustainability of the DMD franchise and market penetration of ELEVIDYS.
- Gross margin cratered to 9.98% in Q4 2025: Gross margin dropped from 79.9% in Q4 2024 to just 9.98% in Q4 2025, driven by a spike in cost of revenue to $398.7 million. This suggests severe product mix issues or inventory write-downs, undermining profitability.
- Net loss of $282.8 million in Q4 2025: The company swung from net income of $159.0 million in Q4 2024 to a net loss of $282.8 million in Q4 2025, with EPS of -$2.74. Negative trailing net income makes traditional valuation metrics like P/E unusable.
- Negative free cash flow of $317.4 million TTM: Free cash flow was negative $317.4 million on a trailing twelve-month basis, indicating the company is burning cash to fund operations. This reliance on external financing adds financial risk.
SRPT Technical Analysis
As of July 17, 2026, SRPT trades at $17.22, reflecting a 1-year price decline of 21.6% and a 52-week range of $10.42 to $25.32. The current price sits at 46% of the 52-week range, indicating it is closer to the low end, which could suggest a potential value opportunity but also reflects persistent bearish sentiment. The stock has been in a broad downtrend over the past year, with the 52-week low of $10.42 representing a significant support level. Over the last 3 months, SRPT has declined 20.1%, while the S&P 500 gained 4.7%, showing severe relative underperformance. The 1-month price change is +1.5%, slightly positive but lagging the S&P 500's +0.3% gain, indicating tentative short-term stabilization. However, the 3-month decline of 20.1% versus the S&P 500's +4.7% highlights persistent selling pressure and a lack of momentum. The beta of 0.20 suggests the stock is significantly less volatile than the market, which is unusual for a biotech and may reflect limited correlation or thin trading. The 52-week high of $25.32 acts as key resistance; a breakout above that level would signal a reversal of the downtrend. Conversely, a breakdown below the 52-week low of $10.42 could trigger further downside. The short ratio of 7.43 days indicates elevated short interest, which could lead to a short squeeze if positive catalysts emerge.
Beta
0.20
0.20x market volatility
Max Drawdown
-45.7%
Largest decline past year
52-Week Range
$10-$25
Price range past year
Annual Return
+21.7%
Cumulative gain past year
| Period | SRPT Return | S&P 500 |
|---|---|---|
| 1m | -7.5% | +0.2% |
| 3m | -21.5% | +5.2% |
| 6m | -25.6% | +8.6% |
| 1y | +21.7% | +19.0% |
| ytd | -23.9% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SRPT Fundamental Analysis
Sarepta's revenue trajectory has been volatile: Q4 2025 revenue was $442.9 million, down 32.7% year-over-year from $658.4 million in Q4 2024, reflecting a significant deceleration. However, full-year 2025 revenue (Q1-Q4) totaled $2.20 billion, up from $1.90 billion in 2024, driven by earlier quarters. The Q4 2025 decline was partly due to a high base from prior-year ELEVIDYS launches. Revenue segments show EXONDYS 51 contributed $115.6 million, AMONDYS 45 $26.7 million, and VYONDYS 53 $24.7 million in the most recent quarter, indicating reliance on the DMD franchise. The company swung to a net loss of $282.8 million in Q4 2025 from a net income of $159.0 million in Q4 2024, with EPS of -$2.74 versus +$1.65. Gross margin collapsed to 9.98% in Q4 2025 from 79.9% in Q4 2024, driven by a spike in cost of revenue to $398.7 million, likely due to inventory adjustments or product mix. Operating margin was -92.9% in Q4 2025, reflecting high R&D spending of $325.3 million and SG&A of $128.3 million. The company is unprofitable on a trailing twelve-month basis, with net income of -$282.8 million in Q4 2025 alone, though it had profitable quarters in Q2 2025 and earlier periods. Sarepta's balance sheet shows $814.4 million in cash at end of Q4 2025, with a current ratio of 2.32 and debt-to-equity of 0.91, indicating manageable leverage. However, free cash flow was negative $317.4 million on a trailing twelve-month basis, and operating cash flow was negative $583.4 million in Q1 2025, though it turned positive in Q2 and Q4 2025. ROE is negative at -62.5%, reflecting persistent losses relative to equity. The company relies on external financing and cash reserves to fund operations, as free cash flow has been inconsistent.
Quarterly Revenue
$442934000.0B
2025-12
Revenue YoY Growth
-32.7%
YoY Comparison
Gross Margin
10.0%
Latest Quarter
Free Cash Flow
$-317427000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SRPT Overvalued?
Since net income is negative (TTM net loss of $282.8 million), the trailing P/E ratio of -3.02 is not meaningful. Therefore, we use the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S ratio is 5.09, while the forward P/S (based on estimated revenue of $1.28 billion) is approximately 1.03, implying the market expects significant revenue growth or margin improvement. The gap between trailing and forward P/S suggests optimism about future sales expansion. Compared to the biotechnology industry average P/S of roughly 6.5x (estimated), Sarepta's trailing P/S of 5.09x represents a 22% discount, which may be justified by its negative profitability and volatile revenue. However, the forward P/S of 1.03x is extremely low, potentially indicating deep value if revenue estimates are met. Historically, Sarepta's P/S ratio has ranged from 5x to over 40x over the past five years. The current trailing P/S of 5.09x is near the low end of its historical range, suggesting the stock is cheap relative to sales compared to its own history. This could imply a value opportunity if the company can stabilize earnings, but it may also reflect structural concerns about growth sustainability.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 2x~89x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-3.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Sarepta's financial health is under strain. The company reported a net loss of $282.8 million in Q4 2025, swinging from a profit of $159.0 million a year earlier, and free cash flow was negative $317.4 million on a trailing twelve-month basis. Gross margin collapsed to 9.98% in Q4 2025 from 79.9% in Q4 2024, driven by a spike in cost of revenue to $398.7 million, which may indicate inventory write-downs or unfavorable product mix. With $814.4 million in cash and a debt-to-equity ratio of 0.91, the company has some buffer, but the negative operating cash flow of $583.4 million in Q1 2025 highlights the risk of cash burn if revenue does not recover.
Market & Competitive Risks: The stock trades at a trailing P/S of 5.09x, a 22% discount to the biotech industry average of ~6.5x, but this discount may be justified by negative profitability and volatile revenue. The beta of 0.20 is unusually low for a biotech, suggesting limited correlation with the market, which could be a double-edged sword if sector rotation favors growth stocks. The wide analyst target range ($5 to $38) reflects deep uncertainty, and the consensus Hold rating indicates that analysts are waiting for clearer signs of sustainable profitability. Competitive pressures from other DMD therapies and potential regulatory setbacks for pipeline candidates are ongoing threats.
Worst-Case Scenario: In a severe adverse scenario, Sarepta could face continued revenue declines, further margin compression, and a loss of investor confidence, driving the stock to its 52-week low of $10.42 or even the analyst low target of $5.00. From the current price of $17.22, a drop to $10.42 would represent a loss of approximately 39.5%, while a decline to $5.00 would represent a 71% loss. This scenario could be triggered by a failed pipeline trial, a major competitive setback, or an inability to reverse the Q4 2025 revenue decline.